Chenxin Pharmaceutical Co., Ltd. is not a state-owned enterprise, but a private enterprise. Chenxin Pharmaceutical Co., Ltd. is currently listed on the main board of the Shanghai Stock Exchange (stock abbreviation: Chenxin Pharmaceutical, stock code: 603367). It is a comprehensive pharmaceutical company integrating R&D, production and sales. It is located in Jining City, Shandong Province.
Development History
The company was founded in 1970, formerly known as Jining No. 3 Pharmaceutical Factory. In 1998, it was renamed and established as Shandong Lukang Chenxin Pharmaceutical Co., Ltd., and in 2011 it was renamed Chenxin Pharmaceutical Co., Ltd.
Company Honors
On August 31, 2021, Chenxin Pharmaceutical Co., Ltd. passed the review evaluation of the 2021 National Technology Innovation Demonstration Enterprise. On January 28, 2022, the notice issued by the National Development and Reform Commission and other departments on the issuance of the new certification and the list of all national enterprise technology centers in 2021 (28th batch) showed that this enterprise technology center has the qualification of a national enterprise technology center.
The company has a history of nearly 40 years of comprehensive chemical preparation production. It is a national high-tech enterprise, a postdoctoral research workstation, a Shandong Enterprise Technology Center, and a Shandong Antibiotic Engineering Technology Research Center. It has obtained the National Development and Reform Commission Industrial Cultural Support Fund, China Patent Shandong Star Enterprise and other honors.
Company business scope
Licensed items: pharmaceutical production; pharmaceutical commissioned production; special medical formula food production; food production; health food production; beverage production; food additive production; pharmaceutical import exit. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments) General projects: sales of formula foods for special medical purposes; food sales (only sales of pre-packaged foods ); Internet sales of food (only sales of prepackaged food); sales of health food (prepackaged); sales of food additives; import and export of goods; import and export of technology; medical research and experimental development; technical services, technology development, technical consultation, and technical exchanges , technology transfer, technology promotion; engage in investment activities with its own funds. (Except for projects that require approval according to law, business activities can be carried out independently with a business license)
Company Philosophy
Adhering to the concept of "innovating through the old, being honest and trustworthy", Chenxin Pharmaceutical is based on It is our responsibility to protect the lives of patients and is committed to independent research and development and production of drugs that can fill the domestic gap and have independent intellectual property rights. Adefovir dipivoxil (and tablets) independently developed by the company has been approved by the National Class I New Drug Certificate.
The company and Jining University (I would like to express my gratitude to the students of Jining University for their hard work in the workshop, and thank you again), China Pharmaceutical University, Shenyang Pharmaceutical University, Shandong University, and Shandong Pharmaceutical Industry Research Institute , the Institute of Materia Medica of the Chinese Academy of Sciences, the Academy of Military Medical Sciences and other scientific research institutes have established long-term cooperative relationships, and have successfully embarked on a path of "joint innovation among industry, academia and research". Chenxin Pharmaceutical has successfully developed more than 100 new varieties, including 1 national Class I new drug, 8 Class II new drugs, and 36 Class IV new drugs. It has obtained more than 60 new drug certificates and more than 90 production approvals. .